STING1 and neoplasm: Despite the profound antitumor immune responses produced by current small-molecule STING agonists, their clinical translation faces challenges, including rapid clearance, low efficacy for tumor targeting, and the risk of random diffusion leading to unwanted autoimmune toxicity.